TNFRSF1B and neoplasm: Fu et al. (2021[19]) implemented this concept in practice and discovered that the combination of anti-TNFR2 and anti-PD-L1 resulted in significant tumor efficacy, enhanced intratumor CD8+ T cells, reduced Tregs, and increased IFN-gamma levels, indicating that receptor-proximal rewiring can unlock checkpoint efficacy.